Valproic Acid for Autosomal Dominant Forms of RP
Description: In preclinical studies and limited clinical evaluations, valproic acid has shown the potential to slow the progress of vision loss from autosomal dominant forms of retinitis pigmentosa (RP). Valproic acid is a drug FDA approved for the treatment of seizure disorders. The Foundation Fighting Blindness Clinical Research Institute, the clinical trial support organization of the Foundation Fighting Blindness, is funding a three-year, 90-participant Phase II clinical trial at the Retina Foundation of the Southwest (Dallas) and the University of Utah (Salt Lake City) to evaluate the safety and efficacy of valproic acid. Participants must be at least 18 years of age and have a diagnosis of autosomal dominant retinitis pigmentosa. Participants will be randomized to receive either placebo or valproic acid.
Trial Status: Recruiting participants.
Articles on Valproic Acid:
FDA-Approved Drug Moving into Clinical Trial for Treatment of RP
Participants Recruited for Valproic Acid Clinical Trial
Valproic Acid Clinical Trial FAQ — Includes Inclusion and Exclusion Criteria
Partial List of Participation Criteria:
- Diagnosis of autosomal dominant retinitis pigmentosa
- At least 18 years of age
- Women must not be pregnant (and take precautions to avoid pregnancy)
- Participants must not be currently receiving valproic or other anticonvulsants
Kirsten Locke, R.N.
(214) 363-3911 ext 114
Retina Foundation of the Southwest (Dallas, Texas)
Kim Wegner, R.N.
University of Utah
Dr. Barbara Jennings
University of Tennessee -- Hamilton Eye Institute (Memphis)
University Of Miami, Miller School of Medicine
Starting in June 2012
Catie Beattie, MS, CGC
Casey Eye Institute
Oregon Health & Science University (Portland)
Pam Titus, COT
Kellogg Eye Center
University of Michigan (Ann Arbor)
Valproic acid clinical trial listing on ClinicalTrials.gov